BACKGROUND: Chemokines play a key role in the recruitment of the immune cells into the autoimmune process. Thus, the simultaneous evaluation of circulating levels of Th1-related chemokines, such as CX chemokine ligand 10 (CXCL10) and macrophage inflammatory proteins 1α (CCL3/MIP-1α), and Th2-related chemokines, such as macrophage inflammatory proteins 1 β (CCL4/MIP-1β) could be useful in the approach to some autoimmune diseases, including autoimmune Addison's disease (AAD). AIM: To evaluate plasmatic levels of MIP-1α, MIP-1β, CXCL10 and adrenocortical antibodies in patients with AAD under treatment with corticosteroids. PATIENTS AND METHODS: Twelve women and 5 men (group 1) were divided in 2 subgroups: 9 subjects with isolated AAD (group 1a) and 8 with AAD associated with chronic autoimmune thyroiditis (group 1b). MIP-1α, MIP- 1β and CXCL10 were evaluated in the serum of all patients and in 20 healthy controls, using a system for microarray suspension. RESULTS: The levels of MIP-1α, MIP-1β and CXCL10 resulted significantly increased vs controls (p<0.001). An inverse significant correlation between the serum levels of MIP- 1β and the duration of the disease was observed. CONCLUSION: High levels of MIP-1α and MIP-1β associated with increased levels of CXCL10 in AAD seem to indicate a role of these chemokines in the autoimmune pathology of adrenal gland through the recruitment in loco of Th1 and Th2 cells. The simultaneous measurement of Th1-related chemokines (CXCL10 and MIP-1α) and of Th2-related chemokine MIP-1β in the serum of patients with AAD would sustain a novel preliminary hypothesis on the immune microenvironment of chronic autoimmune inflammation within adrenal glands.
BACKGROUND: Chemokines play a key role in the recruitment of the immune cells into the autoimmune process. Thus, the simultaneous evaluation of circulating levels of Th1-related chemokines, such as CX chemokine ligand 10 (CXCL10) and macrophage inflammatory proteins 1α (CCL3/MIP-1α), and Th2-related chemokines, such as macrophage inflammatory proteins 1 β (CCL4/MIP-1β) could be useful in the approach to some autoimmune diseases, including autoimmune Addison's disease (AAD). AIM: To evaluate plasmatic levels of MIP-1α, MIP-1β, CXCL10 and adrenocortical antibodies in patients with AAD under treatment with corticosteroids. PATIENTS AND METHODS: Twelve women and 5 men (group 1) were divided in 2 subgroups: 9 subjects with isolated AAD (group 1a) and 8 with AAD associated with chronic autoimmune thyroiditis (group 1b). MIP-1α, MIP- 1β and CXCL10 were evaluated in the serum of all patients and in 20 healthy controls, using a system for microarray suspension. RESULTS: The levels of MIP-1α, MIP-1β and CXCL10 resulted significantly increased vs controls (p<0.001). An inverse significant correlation between the serum levels of MIP- 1β and the duration of the disease was observed. CONCLUSION: High levels of MIP-1α and MIP-1β associated with increased levels of CXCL10 in AAD seem to indicate a role of these chemokines in the autoimmune pathology of adrenal gland through the recruitment in loco of Th1 and Th2 cells. The simultaneous measurement of Th1-related chemokines (CXCL10 and MIP-1α) and of Th2-related chemokine MIP-1β in the serum of patients with AAD would sustain a novel preliminary hypothesis on the immune microenvironment of chronic autoimmune inflammation within adrenal glands.
Authors: A De Bellis; A Bizzarro; R Rossi; V A Paglionico; T Criscuolo; G Lombardi; A Bellastella Journal: J Clin Endocrinol Metab Date: 1993-04 Impact factor: 5.958
Authors: C Betterle; M Volpato; B Rees Smith; J Furmaniak; S Chen; R Zanchetta; N A Greggio; B Pedini; M Boscaro; F Presotto Journal: J Clin Endocrinol Metab Date: 1997-03 Impact factor: 5.958
Authors: C Betterle; M Volpato; B Rees Smith; J Furmaniak; S Chen; N A Greggio; M Sanzari; F Tedesco; B Pedini; M Boscaro; F Presotto Journal: J Clin Endocrinol Metab Date: 1997-03 Impact factor: 5.958
Authors: B O Roep; F S Kleijwegt; A G S van Halteren; V Bonato; U Boggi; F Vendrame; P Marchetti; F Dotta Journal: Clin Exp Immunol Date: 2010-01-05 Impact factor: 4.330
Authors: Silje W Syversen; Guro L Goll; Espen A Haavardsholm; Pernille Bøyesen; Tor Lea; Tore K Kvien Journal: Arthritis Res Ther Date: 2008-03-02 Impact factor: 5.156
Authors: S Laureti; A De Bellis; V I Muccitelli; F Calcinaro; A Bizzarro; R Rossi; A Bellastella; F Santeusanio; A Falorni Journal: J Clin Endocrinol Metab Date: 1998-10 Impact factor: 5.958
Authors: Luka Brčić; Ana Barić; Benjamin Benzon; Marko Brekalo; Sanda Gračan; Dean Kaličanin; Veselin Škrabić; Tatijana Zemunik; Maja Barbalić; Ivana Novak; Valdi Pešutić Pisac; Ante Punda; Vesna Boraska Perica Journal: Sci Rep Date: 2020-02-04 Impact factor: 4.379